If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
40
results.
Updated on
13/02/2026 [07:23:00]
Absstract of: US20260035336A1
The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
Absstract of: US20260034202A1
The disclosure provides a sub-micron particle comprising a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains surrounding the lipid structure. The first payload molecule is a macromolecule, optionally a nucleic acid. Additionally, the hydrophobicity of the amphiphilic polymer chains changes in response to an external stimulus.
Absstract of: US20260034223A1
The present disclosure provides polymeric matrices comprising calreticulin (CRbT) and methods of producing and using such matrices. The polymeric matrices are useful in treatment of wounds (e.g., chronic diabetic wound).
Absstract of: US20260034236A1
A drug complex may include a target recognition molecule bonded to a copolymer X including structural units of (A), (B), and (C):R1, R2, and R3 being independently H or C1-3 alkyl, R4 being C1-3 alkyl, R5 being H, C1-18 alkyl, 3- to 8-membered cycloalkyl optionally being substituted, adamantyl, C6-18 aryl optionally being substituted, or 5- to 10-membered heteroaryl group optionally being substituted, X1, X2, and X3 being independent O, S, or N—R7, R6 being H, leaving group, or linker, R7 being H or C1-3 alkyl group, m being 1 to 100, and n being 0 to 3.
Absstract of: US20260034198A1
A nanozyme-loaded nucleus pulposus matrix hydrogel microsphere is provided. A simple-to-prepare LOX—MnO2 nanozyme is provided, and the simple-to-prepare LOX—MnO2 nanozyme is loaded onto the GDNP, and an LOX—MnO2-loaded and glucose-enriched decellularized nucleus pulposus hydrogel microsphere, namely the nanozyme-loaded nucleus pulposus matrix hydrogel microsphere is formed through a new two-stage temperature-controlling microfluidic system.
Absstract of: US20260034230A1
The present invention provides, in part, protein-drug conjugates comprising an anti-transferrin receptor (e.g., human transferrin receptor) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain or muscle). Methods for treating various diseases or disorders, such as neurological diseases or muscular diseases, with the conjugates are provided.
Absstract of: US20260034071A1
The present disclosure is based, at least in part, on the discovery that high-purity PEG lipids exhibit superior physical and biological properties, particularly when used in lipid nanoparticle (LNP) formulations. Therefore, the present disclosure provides PEG lipids at a recommended purity, e.g., for use in formulations, such as LNP formulations. The present disclosure also provides LNPs comprising the high-purity PEG lipids, and methods for delivering therapeutic agents to a subject using the same.
Absstract of: US20260034070A1
The disclosure relates to block copolymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods thereof. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides.
Absstract of: US20260035338A1
Provided are an amino lipid compound for preparing a lipid nanoparticle for delivering an active ingredient and a preparation method therefor, a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and the use thereof.
Absstract of: US20260034072A1
Described herein are compositions and methods for treating peripheral artery diseases, including a composition comprising a nanoparticle defining an interior volume and an exterior surface; a payload disposed within the interior volume of the nanoparticle; and a cellular membrane coating disposed on or encapsulating the exterior surface of the nanoparticle; wherein the cellular membrane coating comprises an ICAM1 binding ligand.
Absstract of: WO2026030275A1
The present disclosure relates to RNA molecules encoding an EBV polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of infectious mononucleosis, and other diseases associated with EBV infection.
Absstract of: US20260034069A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Absstract of: US20260034172A1
The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., microparticles comprising a core, a metal shell, and a metal/dielectric interface) and methods for delivering such particles via topical application.
Absstract of: US20260034168A1
An immuno-nanoparticle construct for use in therapeutic applications includes a nanocarrier, a stimulator of interferon (IFN) genes (STING) pathway agonist, and a toll-like receptor 4 (TLR4) agonist, wherein the STING pathway agonist and the TLR4 agonist are co-loaded in the nanoparticle carrier.
Absstract of: WO2024141955A1
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.
Absstract of: EP4686417A1
The subject of the invention are nano/microcapsules with an average diameter of 0.1 µm to 5 µm having a coating with a thickness of 5 nm to 100 nm encapsulating a core, characterised in that the coating (4) of the nano/microcapsules (1) contains pectin supplied for the preparation of the nano/microcapsules (1) in the fruit pulp, and the core (3) is a water-oil nanoemulsion containing bioactive components (6, 7). The subject of the application is also a health-promoting product containing these nano/microcapsules and the method of obtaining them.
Absstract of: CN120897991A
The present invention relates to chimeric antigen receptor constructs and their use for therapy and therapy. Further disclosed are methods of treating and/or preventing a disease such as, for example, cancer, an infectious disease, an inflammatory or inflammation-inducing disease, a chronic disease, or an autoimmune disease.
Absstract of: CN120835876A
The present invention relates to: an ionized lipid comprising a lipid having a branched structure; lipid nanoparticle formulations using the ionized lipids and uses thereof. The ionized lipid provided by the invention is a biodegradable lipid material, and a branched heteroamine structure exists in the lipid structure of the ionized lipid. Moreover, the lipid nanoparticles using the ionized lipid can efficiently deliver nucleic acid drugs and the like, and thus can be effectively used in related technical fields, such as mRNA vaccines and therapeutic agents.
Absstract of: MX2025008266A
A mixture for treating a tumor, which includes an agent which turns into a hydrogel by addition of calcium ions, a vehicle carrying the agent in a manner allowing injection of the mixture into a tumor; and radium radionuclides bonded to the agent in a concentration sufficient to treat the tumor by radiotherapy.
Absstract of: CN120936714A
The present invention relates to methods of environment-specific or cellular environment-specific gene regulation, as well as related nucleic acid constructs, cells and therapeutic uses and methods. In particular, the present invention relates to the inhibition of environmentally specific expression of RNA in a cell in order to regulate the expression of one or more target genes in said cell in an environmentally specific manner.
Absstract of: US20260001838A1
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve targeted delivery of therapeutic cargo without the need for a targeting ligand are also provided.
Absstract of: ZA202305748B
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.
Absstract of: CN121445708A
本发明涉及一种靶向递送丁酸的OSA淀粉‑多糖互穿网络微球的制备方法，包括：S1、将多孔淀粉与辛烯基琥珀酸酐进行酯化反应，得到OSA淀粉；S2、将丁酸钠与玉米醇溶蛋白溶于醇溶液中，搅拌进行包埋，得到玉米醇溶蛋白‑丁酸钠；S3、将OSA淀粉与玉米醇溶蛋白‑丁酸钠进行反应，得到复合物；S4、将复合物分散于海藻酸钠溶液中，再滴加到氯化钙溶液中进行交联，得到OSA淀粉‑多糖凝胶微球，然后将其浸泡于第一浓度的壳聚糖溶液中进行一次包覆，再浸泡于第二浓度的壳聚糖溶液中进行二次包覆；第一浓度低于第二浓度，第一浓度和第二浓度相差不低于1wt％。本发明通过构建内核‑载体‑互穿网络外壳的结构，解决丁酸递送中包封率低、靶向性差、稳定性弱的难题。
Absstract of: CN121445905A
本发明涉及一种肿瘤内质网靶向的稀土纳米诊疗一体化制剂及其制备方法和应用，所述稀土纳米诊疗一体化制剂包括稀土核壳纳米颗粒以及负载在稀土核壳纳米颗粒表面的肿瘤靶向肽和内质网信号肽；所述稀土核壳纳米颗粒包括稀土纳米颗粒NaYbF4:Er/Ce/Zn和覆盖于NaYbF4表面的CaF2。该稀土纳米诊疗一体化制剂能够依赖精准的内质网靶向Ca²⁺释放，诱导肿瘤细胞钙过载，从而触发免疫原性细胞死亡并激活抗肿瘤免疫反应；同时，借助稀土纳米颗粒稳定的NIR‑Ⅱ区荧光特性，实现对肿瘤病灶的高灵敏成像与实时监测，兼具精准诊断与高效治疗的一体化优势。
Nº publicación: CN121450645A 03/02/2026
Applicant:
温州医科大学
Absstract of: CN121450645A
本发明属于生物医药与分子生物学领域，具体涉及一种新型的正交复制RNA、制备方法及其应用。所述正交复制RNA的序列包含：(a) 人诺如病毒的5'非翻译区；(b)人诺如病毒的开放阅读框1，其编码复制酶；(c) 目的基因的反义编码序列；(d) 复制终止信号和3'非翻译区；所述正交复制RNA在细胞内复制后，能够产生5'端共价连接有Vpg蛋白的、可翻译所述目的基因的正义mRNA。本申请首次将huNoV复制子成功工程化为治疗性OrepRNA平台，创造了全新的RNA药物载体类别，可以实现低免疫原性、高保真性，突破帽依赖性翻译受限的疾病治疗瓶颈。该平台通过匹配不同治疗基因可解决多种病理机制迥异的疾病，延展性强，为肿瘤恶病质、GVHD肺纤维化等难治性疾病提供突破性治疗方案。
BOPI
Electronic site
